Annovis Bio, Inc.
(NYSE Amex Equities : ANVS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.60%162.570.7%$1033.19m
MRKMerck & Co., Inc. -0.65%76.730.7%$981.19m
LLYEli Lilly & Co. -1.18%219.601.1%$901.61m
PFEPfizer Inc. -1.46%38.910.9%$888.18m
ABBVAbbVie, Inc. -1.44%113.251.9%$722.70m
BMYBristol-Myers Squibb Co. -0.63%66.351.0%$618.54m
AZNAstraZeneca Plc -1.00%57.771.2%$393.63m
OGN -3.56%30.340.0%$316.55m
ANVSAnnovis Bio, Inc. 3.09%92.830.0%$315.87m
NVSNovartis AG -1.08%93.140.2%$179.91m
GSKGlaxoSmithKline Plc -1.89%39.810.2%$149.37m
NOVNNovan, Inc. 0.65%10.925.8%$140.79m
ORPHOrphazyme A/S -48.01%7.570.0%$122.93m
BTXBrooklyn ImmunoTherapeutics, Inc. 12.09%17.2012.4%$106.49m
CNSTConstellation Pharmaceuticals, Inc. -0.27%33.730.0%$104.56m

Company Profile

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.